Lyme Disease Intravenous Treatment
Customize your policy alerts
Sign up for EmblemHealth Policy MG.MM.ME.57d alerts
Get alerted when Policy MG.MM.ME.57d changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity criteria, acceptable agents, exclusions, and coding for IV antibiotic therapy for members with confirmed Lyme disease; applies to providers requesting preauthorization from EmblemHealth.
Doxycycline added as medically necessary for members intolerant to b-lactam antibiotics.
Repeat or prolonged courses of IV antibiotics not considered medically necessary changed from >4 weeks to >8 weeks.
Coverage Criteria for IV Antibiotic Therapy (Lyme Disease)
Initial IV Therapy
Covered when ANY of the following are met for members with confirmed Lyme disease
From policy Section I
Medically Necessary IV Antibiotics
Medically necessary IV therapy agents include:
From policy Section II
Repeat Outpatient IV Therapy
Repeat 2-4-week outpatient IV therapy is medically necessary when ALL of the following are met
From policy Limitations II
Intravenous therapy with certain agent classes is not considered medically necessary for treatment of Lyme disease due to insufficient evidence of therapeutic value. Specifically, IV administration of carbapenems (e.g., doripenem, ertapenem, imipenem, meropenem), first‑generation cephalosporins (e.g., cefazolin), azole antifungals, and fluoroquinolones (e.g., levofloxacin, moxifloxacin) are excluded from coverage.
Repeat or prolonged outpatient intravenous antibiotic courses beyond the policy threshold are not considered medically necessary. The policy specifies that repeat or prolonged courses of IV antibiotics >8 weeks have not been shown to improve net health outcomes and therefore are excluded from coverage.
Procedure and Duration Coding
| 96365 | Intravenous infusion; initial, up to 1 hour |
| 96366 | Intravenous infusion; each additional hour |
| 96369 | Subcutaneous infusion; initial, up to 1 hour, including pump set-up and establishment of subcutaneous infusion site(s) |
| 96370 | Subcutaneous infusion; each additional hour |
| 96371 | Subcutaneous infusion; additional pump set-up with establishment of new subcutaneous infusion site(s) |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance/drug |
| 96375 | Therapeutic, prophylactic, or diagnostic injection; each additional sequential intravenous push of a new substance/drug |
| 96376 | Therapeutic, prophylactic, or diagnostic injection; each additional sequential intravenous push of the same substance/drug (facility) |
| 99601 | Home infusion/specialty drug administration, per visit (up to 2 hours) |
| 99602 | Home infusion/specialty drug administration, each additional hour |
Provider Requirements and Authorization
Prior authorization required; include infusion/home-infusion codes
Preauthorization is required for IV antibiotic therapy; submit clinical documentation that the member meets the policy medical necessity criteria. Applicable procedure codes for infusion and home infusion (listed in the policy) must be included with the authorization request: 96365, 96366, 96369, 96370, 96371, 96374, 96375, 96376, 99601, 99602.
- Include the member's confirmed Lyme disease diagnosis and which Initial IV Therapy indication (A–D) is met.
- Attach planned infusion procedure code(s) from the policy (CPT 96365–96376) or home infusion codes (99601–99602).
Prior oral therapy and repeat IV therapy prerequisites
For Lyme arthritis, IV therapy is eligible only after failure to respond to a 4‑week course of appropriate oral antibiotic therapy. Repeat outpatient IV therapy (2–4 week courses) is allowed only when the member previously completed an initial IV course and has objective evidence of relapse, progression, or a new focus of organ damage.
- Document prior completion and lack of response to a 4‑week oral antibiotic course for Lyme arthritis.
- For repeat IV therapy, document prior initial IV course completion and objective evidence (labs/imaging) within the timeframe required by the policy.
Submit clinical evidence (prior therapy, labs, imaging) with request
The treating physician or primary care provider must submit clinical evidence demonstrating the member meets the policy criteria (examples include documentation of prior oral therapy failure for arthritis, relevant laboratory or CSF results, and imaging findings). This documentation is required to obtain preauthorization.
- Examples of clinical evidence: prior oral antibiotic course details, CSF analysis results, MRI findings, and lab results confirming Lyme disease.
- For repeat outpatient IV therapy, provide lab results obtained within the past 3 months and documentation of the initial IV course.
Missing documentation may lead to denial
Failure to submit the required clinical evidence that the member meets the policy criteria may prevent preauthorization or payment and may result in denial on post‑payment review.
- Missing documentation may include absence of prior oral therapy details, lack of CSF or imaging results, or no proof of completion of an initial IV course.
- Ensure infusion procedure codes are included with the clinical documentation to support billing and authorization.
Background
Lyme disease may present as localized or disseminated infection affecting joints, heart, and the nervous system; IV antibiotics are reserved for specific organ‑involving manifestations or situations where oral therapy is inadequate. Indications that may justify IV therapy include refractory Lyme arthritis after an appropriate oral course, moderate‑to‑severe Lyme carditis (for example high‑degree AV block or myopericarditis), neuroborreliosis confirmed by compatible MRI and CSF findings or CSF lymphocytic pleocytosis, and cases in pregnancy with disseminated disease. The policy also clarifies that IV therapy is not appropriate for early localized disease (erythema migrans without systemic manifestations), flu‑like syndromes, initial treatment of Lyme arthritis, nonspecific chronic symptoms, prophylaxis of asymptomatic persons with only a positive immunologic test, or treatment strategies previously shown to lack benefit (including repeat/prolonged IV courses beyond 8 weeks and non‑antibiotic modalities listed in the exclusions).
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.